The insider selling scandal over ImClone's miracle cancer drug has posted its own miracle – lining pockets of insiders with $244 million from a company that never made a dime. For the first time, Congressional investigators have uncovered the total damage for investors and others over ImClone's flopped wonder drug Erbitux. The wipeout and stock dumping, which has embroiled high-profile investors such as Martha Stewart in insider trading cases, swept through in a two-month period last year. Documents to be released today in Washington at congressional hearings on the affair show that a legion of executives, directors and other insiders sold their shares to reap windfalls from ImClone's heady promises for Erbitux. "If all these people really believed Erbitux was the next miracle cancer drug, why then did they dump their stock so quickly instead of buying more?" said Ken Johnson, a spokesman for the House panel on Energy and Commerce, which is probing ImClone.